125 related articles for article (PubMed ID: 18617577)
1. Growth hormone excess and the development of growth hormone receptor antagonists.
Higham CE; Trainer PJ
Exp Physiol; 2008 Nov; 93(11):1157-69. PubMed ID: 18617577
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
[TBL] [Abstract][Full Text] [Related]
3. Pegvisomant: current and potential novel therapeutic applications.
Thankamony GN; Dunger DB; Acerini CL
Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone receptor antagonists.
Kohn DT; Kopchick JJ
Minerva Endocrinol; 2002 Dec; 27(4):287-98. PubMed ID: 12511851
[TBL] [Abstract][Full Text] [Related]
5. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone receptor antagonists therapy for acromegaly.
Parkinson C; Trainer PJ
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):419-30. PubMed ID: 10909433
[TBL] [Abstract][Full Text] [Related]
7. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Parkinson C; Trainer PJ
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267
[TBL] [Abstract][Full Text] [Related]
8. Pegvisomant in the treatment of acromegaly.
Parkinson C; Scarlett JA; Trainer PJ
Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
[TBL] [Abstract][Full Text] [Related]
9. Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
Trainer PJ
J Endocrinol Invest; 2003; 26(10 Suppl):44-52. PubMed ID: 15497659
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.
Kopchick JJ; List EO; Kelder B; Gosney ES; Berryman DE
Mol Cell Endocrinol; 2014 Apr; 386(1-2):34-45. PubMed ID: 24035867
[TBL] [Abstract][Full Text] [Related]
11. Pegvisomant. Pharmacia.
Goffin V; Touraine P
Curr Opin Investig Drugs; 2002 May; 3(5):752-7. PubMed ID: 12090548
[TBL] [Abstract][Full Text] [Related]
12. A long-acting GH receptor antagonist through fusion to GH binding protein.
Wilkinson IR; Pradhananga SL; Speak R; Artymiuk PJ; Sayers JR; Ross RJ
Sci Rep; 2016 Oct; 6():35072. PubMed ID: 27731358
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
Drake WM; Parkinson C; Besser GM; Trainer PJ
Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies for acromegaly.
Roelfsema F; Biermasz NR; Romijn JA; Pereira AM
Expert Opin Emerg Drugs; 2005 Nov; 10(4):875-90. PubMed ID: 16262568
[TBL] [Abstract][Full Text] [Related]
16. Endocytosis and Degradation of Pegvisomant and a Potential New Mechanism That Inhibits the Nuclear Translocation of GHR.
Lan H; Li W; Li R; Zheng X; Luo G
J Clin Endocrinol Metab; 2019 Jun; 104(6):1887-1899. PubMed ID: 30602026
[TBL] [Abstract][Full Text] [Related]
17. Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization.
Maamra M; Kopchick JJ; Strasburger CJ; Ross RJ
J Clin Endocrinol Metab; 2004 Sep; 89(9):4532-7. PubMed ID: 15356058
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
19. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs.
Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G
J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660
[TBL] [Abstract][Full Text] [Related]
20. Lipodystrophy in patients with acromegaly receiving pegvisomant.
Bonert VS; Kennedy L; Petersenn S; Barkan A; Carmichael J; Melmed S
J Clin Endocrinol Metab; 2008 Sep; 93(9):3515-8. PubMed ID: 18611977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]